The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy

Jose A. Karam, Jinhai Fan, Jennifer Stanfield, Edmond Richer, Elie A. Benaim, Eugene P Frenkel, Peter Antich, Arthur I Sagalowsky, Ralph P Mason, Jer-Tsong Hsieh

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The long-term disease-free survival in patients with metastatic transitional cell carcinoma (TCC) is still considerably low. Novel chemotherapeutic agents are needed to decrease the morbidity and mortality of TCC. In this study, we have evaluated several epigenetic modifiers for their therapeutic application in bladder cancer. Both histone deacetylase inhibitors (FK228, TSA) and DNA hypomethylating agent (5-Azacytidine) were tested using in vitro assays such as cell viability, cell cycle analysis and western blot to determine their mechanisms of action. Drug combination experiments were also designed to study any additive or synergistic effects of these agents. In addition, two bladder cancer xenograft models (one subcutaneous and one orthotopic) were employed to assess the therapeutic efficacy of these agents in vivo. Three agents exhibited various growth inhibitory effects on 5 different TCC cell lines in a dose- and time-dependent manner. In addition to G 2/M cell cycle arrest, FK228 is more potent in inducting apoptosis than the two other single agents, and combination of both FK228 and 5-Aza further enhances this effect. p21 induction is closely associated with FK228 or TSA but not 5-Aza, which is mediated via p53-independent pathway. Consistent with in vitro results, FK228 exhibited a significant in vivo growth inhibition of TCC tumor in both subcutaneous and orthotopic xenograft models. FK228 is a potent chemotherapeutic agent for TCC in vivo with minimal undesirable side effects. The elevated p21 level mediated via p53 independent pathway is a hallmark of FK228 mechanism of action.

Original languageEnglish (US)
Pages (from-to)1795-1802
Number of pages8
JournalInternational Journal of Cancer
Volume120
Issue number8
DOIs
StatePublished - Apr 15 2007

Fingerprint

Azacitidine
Histone Deacetylase Inhibitors
Urinary Bladder Neoplasms
Transitional Cell Carcinoma
DNA
Heterografts
Therapeutics
Drug Combinations
Growth
Cell Cycle Checkpoints
romidepsin
Epigenomics
Disease-Free Survival
Cell Survival
Cell Cycle
Western Blotting
Apoptosis
Morbidity
Cell Line
Mortality

Keywords

  • Bladder cancer
  • Chemotherapy
  • DNA methylation
  • Histone acetylation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. / Karam, Jose A.; Fan, Jinhai; Stanfield, Jennifer; Richer, Edmond; Benaim, Elie A.; Frenkel, Eugene P; Antich, Peter; Sagalowsky, Arthur I; Mason, Ralph P; Hsieh, Jer-Tsong.

In: International Journal of Cancer, Vol. 120, No. 8, 15.04.2007, p. 1795-1802.

Research output: Contribution to journalArticle

Karam, Jose A. ; Fan, Jinhai ; Stanfield, Jennifer ; Richer, Edmond ; Benaim, Elie A. ; Frenkel, Eugene P ; Antich, Peter ; Sagalowsky, Arthur I ; Mason, Ralph P ; Hsieh, Jer-Tsong. / The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. In: International Journal of Cancer. 2007 ; Vol. 120, No. 8. pp. 1795-1802.
@article{f0b4b6a96e3940f4908acd29da4e4676,
title = "The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy",
abstract = "The long-term disease-free survival in patients with metastatic transitional cell carcinoma (TCC) is still considerably low. Novel chemotherapeutic agents are needed to decrease the morbidity and mortality of TCC. In this study, we have evaluated several epigenetic modifiers for their therapeutic application in bladder cancer. Both histone deacetylase inhibitors (FK228, TSA) and DNA hypomethylating agent (5-Azacytidine) were tested using in vitro assays such as cell viability, cell cycle analysis and western blot to determine their mechanisms of action. Drug combination experiments were also designed to study any additive or synergistic effects of these agents. In addition, two bladder cancer xenograft models (one subcutaneous and one orthotopic) were employed to assess the therapeutic efficacy of these agents in vivo. Three agents exhibited various growth inhibitory effects on 5 different TCC cell lines in a dose- and time-dependent manner. In addition to G 2/M cell cycle arrest, FK228 is more potent in inducting apoptosis than the two other single agents, and combination of both FK228 and 5-Aza further enhances this effect. p21 induction is closely associated with FK228 or TSA but not 5-Aza, which is mediated via p53-independent pathway. Consistent with in vitro results, FK228 exhibited a significant in vivo growth inhibition of TCC tumor in both subcutaneous and orthotopic xenograft models. FK228 is a potent chemotherapeutic agent for TCC in vivo with minimal undesirable side effects. The elevated p21 level mediated via p53 independent pathway is a hallmark of FK228 mechanism of action.",
keywords = "Bladder cancer, Chemotherapy, DNA methylation, Histone acetylation",
author = "Karam, {Jose A.} and Jinhai Fan and Jennifer Stanfield and Edmond Richer and Benaim, {Elie A.} and Frenkel, {Eugene P} and Peter Antich and Sagalowsky, {Arthur I} and Mason, {Ralph P} and Jer-Tsong Hsieh",
year = "2007",
month = "4",
day = "15",
doi = "10.1002/ijc.22405",
language = "English (US)",
volume = "120",
pages = "1795--1802",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy

AU - Karam, Jose A.

AU - Fan, Jinhai

AU - Stanfield, Jennifer

AU - Richer, Edmond

AU - Benaim, Elie A.

AU - Frenkel, Eugene P

AU - Antich, Peter

AU - Sagalowsky, Arthur I

AU - Mason, Ralph P

AU - Hsieh, Jer-Tsong

PY - 2007/4/15

Y1 - 2007/4/15

N2 - The long-term disease-free survival in patients with metastatic transitional cell carcinoma (TCC) is still considerably low. Novel chemotherapeutic agents are needed to decrease the morbidity and mortality of TCC. In this study, we have evaluated several epigenetic modifiers for their therapeutic application in bladder cancer. Both histone deacetylase inhibitors (FK228, TSA) and DNA hypomethylating agent (5-Azacytidine) were tested using in vitro assays such as cell viability, cell cycle analysis and western blot to determine their mechanisms of action. Drug combination experiments were also designed to study any additive or synergistic effects of these agents. In addition, two bladder cancer xenograft models (one subcutaneous and one orthotopic) were employed to assess the therapeutic efficacy of these agents in vivo. Three agents exhibited various growth inhibitory effects on 5 different TCC cell lines in a dose- and time-dependent manner. In addition to G 2/M cell cycle arrest, FK228 is more potent in inducting apoptosis than the two other single agents, and combination of both FK228 and 5-Aza further enhances this effect. p21 induction is closely associated with FK228 or TSA but not 5-Aza, which is mediated via p53-independent pathway. Consistent with in vitro results, FK228 exhibited a significant in vivo growth inhibition of TCC tumor in both subcutaneous and orthotopic xenograft models. FK228 is a potent chemotherapeutic agent for TCC in vivo with minimal undesirable side effects. The elevated p21 level mediated via p53 independent pathway is a hallmark of FK228 mechanism of action.

AB - The long-term disease-free survival in patients with metastatic transitional cell carcinoma (TCC) is still considerably low. Novel chemotherapeutic agents are needed to decrease the morbidity and mortality of TCC. In this study, we have evaluated several epigenetic modifiers for their therapeutic application in bladder cancer. Both histone deacetylase inhibitors (FK228, TSA) and DNA hypomethylating agent (5-Azacytidine) were tested using in vitro assays such as cell viability, cell cycle analysis and western blot to determine their mechanisms of action. Drug combination experiments were also designed to study any additive or synergistic effects of these agents. In addition, two bladder cancer xenograft models (one subcutaneous and one orthotopic) were employed to assess the therapeutic efficacy of these agents in vivo. Three agents exhibited various growth inhibitory effects on 5 different TCC cell lines in a dose- and time-dependent manner. In addition to G 2/M cell cycle arrest, FK228 is more potent in inducting apoptosis than the two other single agents, and combination of both FK228 and 5-Aza further enhances this effect. p21 induction is closely associated with FK228 or TSA but not 5-Aza, which is mediated via p53-independent pathway. Consistent with in vitro results, FK228 exhibited a significant in vivo growth inhibition of TCC tumor in both subcutaneous and orthotopic xenograft models. FK228 is a potent chemotherapeutic agent for TCC in vivo with minimal undesirable side effects. The elevated p21 level mediated via p53 independent pathway is a hallmark of FK228 mechanism of action.

KW - Bladder cancer

KW - Chemotherapy

KW - DNA methylation

KW - Histone acetylation

UR - http://www.scopus.com/inward/record.url?scp=33947126086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947126086&partnerID=8YFLogxK

U2 - 10.1002/ijc.22405

DO - 10.1002/ijc.22405

M3 - Article

C2 - 17230511

AN - SCOPUS:33947126086

VL - 120

SP - 1795

EP - 1802

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 8

ER -